Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ikano Therapeutics

Request full access

Developing digital health tools to help researchers track patient data, analyze it, and export it for publication

Saddle Brook, United StatesFounded 1998Biotech & Life Sciences

About Ikano Therapeutics

Ikano Therapeutics, Inc., originally founded as Intranasal Therapeutics Inc. in 1998 by Edwin Cohen, operated as a specialty pharmaceutical company focused on developing and commercializing nasally delivered drug products. In March 2009, the company rebranded to Ikano Therapeutics, a name derived from the Greek word for "enable," to reflect a broader corporate strategy beyond intranasal delivery to a more diversified emphasis on high-impact specialty therapeutic products.

The company's primary focus was on addressing unmet medical needs in the treatment of pain and central nervous system disorders. A key asset in its pipeline was ITI-111, a nasally administered formulation of midazolam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity, also known as cluster seizures, in epilepsy patients aged 12 and older. This product, which later became known as Nayzilam®, was developed as a more practical and acceptable outpatient alternative to existing treatments. In November 2009, Ikano received Orphan Drug designation for this midazolam formulation, a status that provides for seven years of marketing exclusivity.

Ikano Therapeutics successfully raised a total of $57.1 million over three funding rounds, including a Series A of $39.1 million in 2006 and a Series B round in 2009. The investor syndicate included prominent venture capital firms such as SV Health Investors (formerly SV Life Sciences), Tullis Health Investors, Burrill & Company, and F-Prime Capital (formerly Fidelity Biosciences). Following a strategic shift, Michael Ross of SV Life Sciences was appointed Chairman of the Board in 2009. Ultimately, Ikano Therapeutics was acquired by UCB, a global biopharmaceutical company. Reports indicate that Ikano went out of business as an independent entity around November 2010.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
54.8/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
SaaS
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Mar 2009 $18M $72M SV Health Investors · Apjohn ventures · Burrill · Fort Washington Capital Partners —
SERIES A✓Equity / VC Apr 2007 $3.1M $12M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Ikano Therapeutics team growth

Ikano Therapeutics's team grew 0% over the past year.

1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ikano Therapeutics in the Saddle Brook ecosystem

Live from Dealroom

The Ikano Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Eight Roads Ventures
  • SV Health Investors
  • Apjohn ventures
  • Burrill
  • Fort Washington Capital Partners
  • Commonwealth Seed Capital

Other known investors2 additional known investors

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Saddle Brook HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ikano Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ikano Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.